Benecyte
Blood & Organ Banks · North Carolina, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
4233 Technology Dr, Durham, North Caroli...Website
www.benecyte.comRevenue
<$5 MillionIndustry
ZI Rank: 1
About Benecyte
Benecyte Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Benecyte your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Benecyte recently announced quarterly report
Click to see if Benecyte had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Benecyte launches new products
Benecyte, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Benecyte has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Benecyte
Check out if Benecyte is spiking on competitors!
Check if Benecyte has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Company Profile Activity
Activity Insights
Benecyte is experiencing very low activity levels compared to other companies in the Healthcare Services sector.
What does this means?
Benecyte is drawing exceptional interest within the Healthcare Services industry, suggesting notable developments or strong market momentum, learn more about Benecyte.
Top Blood & Organ Banks Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Benecyte
Benecyte specializes in immunotherapy, focusing on CAR-CIK technology to effectively target solid tumors. Their innovative approach utilizes CAR-modified CIK cells, which are immune cells capable of attacking a wide range of cancer cells without prior sensitization. The company aims to simplify manufacturing logistics and reduce costs compared to t... Read More
